Freestone Grove Partners LP Acquires Shares of 168,912 Maplight Therapeutics, Inc. $MPLT

Freestone Grove Partners LP purchased a new position in Maplight Therapeutics, Inc. (NASDAQ:MPLT) during the 2nd quarter, HoldingsChannel reports. The fund purchased 168,912 shares of the company’s stock, valued at approximately $6,054,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in MPLT. Fcpm Iii Services B.V. acquired a new position in shares of Maplight Therapeutics during the 4th quarter valued at about $56,672,000. T. Rowe Price Investment Management Inc. acquired a new position in Maplight Therapeutics during the fourth quarter worth $49,154,000. Goldman Sachs Group Inc. purchased a new position in Maplight Therapeutics during the 4th quarter valued at about $34,026,000. BlackRock Inc. purchased a new position in shares of Maplight Therapeutics in the second quarter valued at approximately $36,741,000. Finally, Nan Fung Group Holdings Ltd acquired a new position in shares of Maplight Therapeutics in the fourth quarter worth $17,060,000.

Insider Transactions at Maplight Therapeutics

In other news, Director Troy Cox bought 15,620 shares of Maplight Therapeutics stock in a transaction on Tuesday, July 28th. The shares were bought at an average cost of $9.52 per share, for a total transaction of $148,702.40. Following the acquisition, the director owned 15,620 shares in the company, valued at approximately $148,702.40. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider James Woodruff Lillie sold 22,082 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $12.54, for a total transaction of $276,908.28. Following the sale, the insider owned 202,380 shares in the company, valued at approximately $2,537,845.20. This trade represents a 9.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.80% of the stock is currently owned by corporate insiders.

Maplight Therapeutics Stock Up 0.5%

NASDAQ:MPLT opened at $12.60 on Friday. The company has a market capitalization of $584.36 million and a PE ratio of -0.30. The stock has a fifty day simple moving average of $23.97 and a 200-day simple moving average of $24.09. Maplight Therapeutics, Inc. has a 52-week low of $9.10 and a 52-week high of $40.43.

Maplight Therapeutics (NASDAQ:MPLT) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($1.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.40) by $0.08. As a group, equities analysts anticipate that Maplight Therapeutics, Inc. will post -5.12 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the stock. Raymond James Financial set a $31.00 target price on shares of Maplight Therapeutics in a report on Friday, August 14th. Benchmark reissued a “buy” rating on shares of Maplight Therapeutics in a research report on Monday, June 22nd. Needham & Company LLC raised their price objective on shares of Maplight Therapeutics from $42.00 to $45.00 and gave the stock a “buy” rating in a research report on Friday, July 10th. Morgan Stanley reissued an “equal weight” rating and issued a $21.00 target price (down from $34.00) on shares of Maplight Therapeutics in a report on Tuesday, July 28th. Finally, Wall Street Zen upgraded shares of Maplight Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 15th. Four research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $29.67.

Maplight Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.